SecBot SecBot
Biotech Drug Report Generated Nov 4, 2026

Zavicefta

PFE·PFIZER INC
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved
Time to market
Already approved and marketed in the EU (since June 2016) and multiple ex-US countries. Pediatric use from birth was authorized by the EMA following a CHMP positive opinion in September 2024.
Why 3/10
Zavicefta is already approved and marketed in the EU and ex-US regions with no pending PDUFA date, pivotal readout, or other hard binary catalyst scheduled in the next 12 months; the CHMP positive opinion for pediatric expansion was issued in September 2024 and is already incorporated. As a mature product within Pfizer's $62.6B revenue base, even a material change in Zavicefta's sales would have negligible impact on PFE shares.
Actionable Insight NEUTRAL

Zavicefta is a mature, marketed product with no upcoming binary catalyst. Watch for generic/biosimilar erosion timelines in ex-US markets and any new resistance data that could shift usage patterns, but neither is likely to move Pfizer's stock given the drug's small revenue contribution.

Price Chart

Loading chart...

Executive Summary

Zavicefta (ceftazidime/avibactam) is an IV antibiotic for multi-drug-resistant Gram-negative infections, approved in the EU since 2016 and marketed by Pfizer in ex-US territories. Pfizer acquired the rights from AstraZeneca in 2016 for $1.5B. In the US, the same drug is sold as Avycaz by AbbVie. Zavicefta is on the WHO Essential Medicines List as a RESERVE-group antibiotic for carbapenem-resistant infections. The drug is a mature, commercial-stage product with no upcoming binary regulatory catalyst. It is a very small contributor to Pfizer's $62.6B annual revenue, making it essentially immaterial to PFE's stock price.

How It Works

Zavicefta combines two active ingredients in one IV infusion: ceftazidime (a cephalosporin antibiotic that kills bacteria by weakening their cell walls) and avibactam (a beta-lactamase inhibitor that blocks enzymes bacteria use to destroy ceftazidime). The avibactam component protects ceftazidime from being broken down, allowing it to work against multi-drug-resistant Gram-negative bacteria that would otherwise be untreatable.

Trial Status

Zavicefta is a marketed drug. Post-approval activities include a Phase 2a pediatric PK study (completed, supporting label expansion from birth) and a post-marketing special investigation in Japan (observational, not yet recruiting as of October 2025). No pivotal Phase 3 trials are ongoing.

The Two-Sided Case

▲ Bull Case4
Zavicefta is on the WHO Model List of Essential Medicines (RESERVE group), ensuring ongoing global demand as a last-resort antibiotic for carbapenem-resistant infections.
EMA has approved pediatric use from birth, expanding the addressable patient population.
The global ceftazidime-avibactam market was estimated at roughly $0.93B in 2025 and is projected to grow at a 4.5-8% CAGR through the early 2030s, driven by rising antimicrobial resistance.
Pfizer acquired ex-US rights in 2016 as part of a broader anti-infective portfolio, providing geographic diversification beyond the US market (where AbbVie markets Avycaz).
▼ Bear Case4
Zavicefta faces competition from other novel beta-lactamase inhibitor combinations (e.g. meropenem-vaborbactam, imipenem-cilastatin-relebactam) that could erode market share.
Emerging resistance to ceftazidime-avibactam itself is a documented risk that could limit future use.
The drug is a very small part of Pfizer's $62.6B total revenue (2025), so even a major sales swing would barely move PFE shares.
Counterfeit Zavicefta vials were traced in a Karnataka fake-drug racket (reported 2025), posing brand/reputation risk in emerging markets.

Upcoming Catalysts

  • No hard binary catalysts (PDUFA, pivotal readout, AdComm) are scheduled for Zavicefta in the next 12 months.
  • Watch for generic entry timelines as patents approach expiry in various ex-US markets.
  • Ongoing real-world evidence studies and antimicrobial stewardship guideline updates could incrementally affect usage.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

PFIZER INC 8-K PFE ·Originating report

Sources · 12

Hover a chip for the title
1 ema.europa.eu2 pfizer.com3 en.wikipedia.org4 ema.europa.eu5 dataintelo.com6 annualreview.pfizer.com7 stockanalysis.com8 medicaldialogues.in9 astrazeneca.com10 cnbc.com11 list.essentialmeds.org12 cdn.pfizer.com